TARGAXAN is licensed in the UK for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age (see section 5.1).
In the pivotal study, 91% of the patients were using concomitant lactulose.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
The links below will redirect you to an alternative site not maintained by Norgine Pharmaceuticals Limited
View the Patient Information Leaflet
View the Summary of Product Characterisitics
Please consult with your Doctor, or other qualified Healthcare Professional before use.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
Last update: January 2016